Expansion through M&A Kintiga has expanded capabilities via acquisitions and partnerships, integrating MAP Patient Access and Biopharmics and aligning with BIAL Pharma UK. This growth enables rapid broadening of services and cross-sell opportunities across Europe in market access, regulatory, and payer strategy.

Recurring Platform Growth The online membership platform creates a recurring revenue channel with ongoing access to experts and tools. Opportunities include enterprise licenses, premium content, and workflow integrations that bundle services across development and market access programs.

Tech-Driven Synergy Strategic fit exists with adjacent drug discovery software ecosystems through Optibrium and related tech. There is potential to bundle market access consulting with discovery software, delivering end to end support from research through reimbursement and expanding reach to biotech and pharma audiences.

European Payer Expertise Kintiga's core capability to navigate Europe s regulatory and payer environments positions it to win mid size and growth stage clients seeking multi market access. Opportunities include HTA dossier support, pricing negotiations, reimbursement strategy, and regulatory submissions across UK and EU.

Mid-Market Growth With a mid size team and revenue footprint, Kintiga is well positioned to serve fast moving biotech startups and mid market pharma needing specialized market access guidance, enabling tailored service packages that scale with client portfolios.